A Biden victory would likely mean increased gun regulation and could further stoke demand for firearms.
Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.
| Website: | www.infi.com |
| Email: | irpr_info@infi.com |
| Main Phone: | +1 617 453-1000 |
| Address: | 1100 Massachusetts Avenue |
| Address 2: | Floor 4 |
| State: | MA |
| City / Town: | Cambridge |
| Country: | US |
| Postal Code: | 02138 |
| Exchange: | NGS |
| CEO: | Adelene Q. Perkins |
| Employees: | 25 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
A Biden victory would likely mean increased gun regulation and could further stoke demand for firearms.
Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)
Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)
For relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma (Image: Verastem)
Stock in TG Therapeutics (TGTX) popped in Wednesday trading, seeing shares bounce 9.11%. Driving the gains appears to be the favorable deal secured by rival Infinity (INFI) with AbbVie (ABBV)
Inscribed into the Bill of Rights, woven into the fabric of our society, and unfortunately responsible for the deaths of countless lives, the right to bear arms has always been as American as
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Stocks pared back early gains to end the first trading day of the week modestly higher on Wall Street, as investors have little in the way of economic datato distract them from speculating on what
Much has been made of the effects of sequestration cuts that went in to effect on March 1 of this year. When it comes to national security in particular, there have been dire warnings about the
The Dow Industrial Average dipped to 13,139.08 then rebounded to 13,195.35 moving above its 50-day and 200-day simple moving average at 13,142.23 and 12,999.65. The Nasdaq dipped to 2971.56 than
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
